This company has been marked as potentially delisted and may not be actively trading. Hologic (HOLX) FDA Approvals Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Hologic's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Hologic (HOLX). Over the past two years, Hologic has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Panther. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. FDA Regulatory Events Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. is a drug developed by Hologic for the following indication: Detect Common Causes of Infectious Gastroenteritis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA Clearance - October 2,2025Fda Clearance Drug: Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.Announced Date: October 2, 2025Indication: Detect Common Causes of Infectious GastroenteritisAnnouncementHologic, Inc announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.AI SummaryHologic, Inc. announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. These new molecular tests are designed to quickly detect the most common bacterial causes of infectious gastroenteritis, such as Salmonella, Campylobacter, Shigella, E. coli (including O157), Vibrio, Yersinia and Plesiomonas. The assays can be run together or in any combination, letting laboratories tailor testing panels to each patient’s needs. This mini-panel approach helps reduce unnecessary tests, streamlines workflows and speeds up time to diagnosis. By providing fast, accurate results, the assays support informed clinical decisions and antimicrobial stewardship, ensuring antibiotics are used only when needed. Testing is performed on Hologic’s fully automated Panther Fusion System, which integrates easily into existing lab operations. This clearance highlights Hologic’s commitment to advancing diagnostic innovation and raising the standard of care for patients with suspected bacterial GI infections.Read Announcement Hologic FDA Events - Frequently Asked Questions Has Hologic received FDA approval? As of now, Hologic (HOLX) has not received any FDA approvals for its therapy in the last two years. What drugs has Hologic submitted to the FDA? In the past two years, Hologic (HOLX) has reported FDA regulatory activity for Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.. What is the most recent FDA event for Hologic? The most recent FDA-related event for Hologic occurred on October 2, 2025, involving Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.. The update was categorized as "FDA Clearance," with the company reporting: "Hologic, Inc announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays." What conditions do Hologic's current drugs treat? Currently, Hologic has one therapy (Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.) targeting the following condition: Detect Common Causes of Infectious Gastroenteritis. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Altimmune FDA EventsGilead Sciences FDA EventsMoleculin Biotech FDA EventsMIRA Pharmaceuticals FDA EventsBeOne Medicines FDA EventsVoyager Therapeutics FDA EventsZenas BioPharma FDA EventsPfizer FDA EventsAgios Pharmaceuticals FDA EventsAgenus FDA EventsArvinas FDA EventsBridgeBio Pharma FDA EventsBriacell Therap FDA EventsBeam Therapeutics FDA EventsCellectis FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Merit Medical Systems FDA Events Alcon FDA Events Zimmer Biomet FDA Events Becton, Dickinson and Company FDA Events DexCom FDA Events Insulet FDA Events Teleflex FDA Events AtriCure FDA Events AngioDynamics FDA Events Abbott Laboratories FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:HOLX last updated on 10/2/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredSpaceX IPO Warning: Before you buy any SpaceX shares, read this.The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hologic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hologic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Clearance - October 2,2025Fda Clearance Drug: Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.Announced Date: October 2, 2025Indication: Detect Common Causes of Infectious GastroenteritisAnnouncementHologic, Inc announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.AI SummaryHologic, Inc. announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. These new molecular tests are designed to quickly detect the most common bacterial causes of infectious gastroenteritis, such as Salmonella, Campylobacter, Shigella, E. coli (including O157), Vibrio, Yersinia and Plesiomonas. The assays can be run together or in any combination, letting laboratories tailor testing panels to each patient’s needs. This mini-panel approach helps reduce unnecessary tests, streamlines workflows and speeds up time to diagnosis. By providing fast, accurate results, the assays support informed clinical decisions and antimicrobial stewardship, ensuring antibiotics are used only when needed. Testing is performed on Hologic’s fully automated Panther Fusion System, which integrates easily into existing lab operations. This clearance highlights Hologic’s commitment to advancing diagnostic innovation and raising the standard of care for patients with suspected bacterial GI infections.Read Announcement
